Fatal adverse events associated with Pembrolizumab in cancer patients: A Meta-analysis.
Conclusion: The risk of fatal adverse events with pembrolizumab may be similar to chemotherapy in cancer patients and may vary with tumor types and its combination with chemotherapy.
PMID: 31985314 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Conferences | Databases & Libraries | Melanoma | Skin Cancer | Study | Toxicology